
FY03/17 Financial Results Briefing







15

20

FY03/17 Business Results

Earnings Highlights

Consolidated Income Statement (vs Plan)

Consolidated Income Statement (YoY)

Monthly Sales Growth Rate

Breakdown of Sales by Product Category

Gross Profit Margin Improvement

SG&A Expenses Improvement

Addressing Drug Price and Medical Care Fee Revisions in Dispensing Business

Consolidated Balance Sheet

Consolidated Cash Flow Statement

FY03/17 Key Measures

3

- Revitalization of Existing Stores through Renovations
- Customer Strategy that Leverages Cocokara Club Card
- Establishing One-to-One (Personalized) Marketing Using Diverse Sales Promotion Media
- Further Store Productivity Improvements

FY03/18 Forecasts

Store Openings and Closings (Actual and Planned)

Consolidated Forecasts

Consolidated Sales & Ordinary Income (Trends and Plan)

Medium-term Plan



FY03/17 Business Results

Earnings Highlights



[OVERVIEW]

(1H)

Sales rose and profit declined in Q1 and Q2 reflecting a drop in bulk purchases of some products by foreign visitors, lower customer traffic amid unfavorable weather, an increase in costs driven by upfront investment, and impact from drug price and medical care fee revisions.

(2H)

Sales and profit rose in Q3 and Q4 due to gross profit margin improvement (which had been a key issue), cost controls, measures to address drug price and medical care fee revisions, and effects from store renovations over the full year.

[Drugstore Operations]

- **External** Sluggish sales of seasonal products (cold medicine, hay fever drugs, etc.) owing to weather factors.
- External From January, impact from lower bulk purchases of some products by foreign visitors eased.
- External Duty-free sales remained firm: Full-Year 98bn (+27.8% YoY)
- Initiative Store renovations \rightarrow Full-Year 67 stores (including and small renovations103 stores)
- Initiative Gross profit margin improvement \rightarrow YoY: 1H-0.1% 2H+0.6% Full-Year+0.2%
- Initiative Cost controls \rightarrow Absorbed upfront spending, and helped keep expense ratio on par with year-earlier level

[Pharmacy Operations]

ExternalDrug price and medical fee revisions, decline in response to year-earlier demand growth for hepatitis C drugsInitiativeCountermeasures helped secure growth in full-year gross profit (YoY+92mn)

Consolidated Income Statement (vs Plan)

こ ココカラファイン

(Million yen)

5

		FY03/17 Plan	FY03/17 Results	vs Plan	vs Plan (%)	Factors
	Net sales	377,500 100.0%	377,203 100.0%	-297	99.9	 ♦ Same-store sales growth (Plan+2.1% → Result+0.8%) • Sluggish sales of seasonal products
	Drugstore & Dispensing	341,270	339,105	-2,165	99.4	 (cold medicine, hay fever drugs, etc.) due to weather factors ♦ New store opening: Plan 20→Result 35
	Wholesale & other	36,230	38,098	+1,868	105.2	Closing∶Plan 30→Result 38 ♦ Increase in clients → rise in wholesale sales
	Gross profit	97,043 25.7%	97,053 25.7%	+10	100.0	 ♦ Steady progress with gross profit margin improvement measures for drugstore product sales (Plan 26.6%→Result 26.7%)
	SG&A	86,943 ^{23.0%}	86,894 ^{23.0%}	-49	99.9	Steady progress with cost control measures
Ор	erating income	10,100 _{2.7%}	10,159 _{2.7%}	+59	100.6	
Or	dinary income	12,500 3.3%	12,507 3.3%	+7	100.1	
	Net income	6,800 _{1.8%}	7,037 1.9%	+237	103.5	


Consolidated Income Statement (YoY)

こ ココカラファイン

(Million yen)

		FY03/16 Results	FY03/17 Results	Change	YoY (%)	Factors influencing YoY changes
	Net sales	373,275 100.0%	377,203 100.0%	+3,928	101.1	 Same-store sales growth: +0.8% Revitalization policy centered on existing store renovation Fluctuations in inbound-related sales
	Drugstore & Dispensing	339,646	339,105	-541	99.8	 (duty-free sales up, bulk purchases down) Calendar effect (2016 was leap year) Pushed down by drug price/medical service fee revisions Decline in response to year-earlier
	Wholesale & other	33,629	38,098	+4,469	113.3	demand growth for hepatitis C drugs ♦ New store openings: 35 Closings: 38 ♦ Iwasaki Kohkendo FYE change(Feb.→Mar.) → one less month of sales(15bn) ♦ Increase in clients → rise in wholesale sales
	Gross profit	96,068 25.7%	97,053 25.7%	+985	101.0	 Higher share of wholesale sales weighed down gross profit margin Gross profit margin for drugstore product sales declined in 1H, but improved in 2H (YoY:1H-0.1% 2H+0.6% Full-Year+0.2%)
	SG&A	84,949 ^{22.8%}	86,894 ^{23.0%}	+1,945	102.3	 Increase in SG&A-to-sales ratio Increase in number of pharmacists, upfront spending on store renovations, and other factors in 1H
Ор	erating income	11,119 3.0%	10,159 _{2.7%}	-960	91.4	♦ Reduction in Operating income •1H:-1,466 2H:+506
Or	dinary income	13,461 _{3.6%}	12,507 3.3%	-954	92.9	 Reduction in Ordinary income •1H:-1,411 2H:+458
	Net income 6,927		7,037 1.9%	+110	101.6	 ◇ Extraordinary losses : -564 • Reduction in asset impairment charges (from 1,393 to 945) • Decrease in unprofitable stores (from 53 in FY03/16 to 38 in FY03/17) ◇ Corporate tax rate : from 40.8% to 37.9%

Monthly Sales Growth Rate



Existing Stores Apr.-May: Sluggish demand for summer products
Aug.-Sep.: Decline in number of customers due to bad weather including typhoons
Dec.: Sluggish sales of seasonal (winter) products (cold medicine, etc.) due to weather factors
Feb.: Impact from calendar effect (2016 was leap year)

Corporate

Apr.: Iwasaki Kohkendo FYE change(Feb \rightarrow Mar) \rightarrow one less month of sales(15bn) Feb.: Impact from calendar effect (2016 was leap year)

7

こ ココカラファイン

Breakdown of Sales by Product Category

こ ココカラファイン

	F	Y03/16		FY03/17			
	Million yen	Share (%)	YoY (%)	Millions yen	Share (%)	YoY (%)	
Pharmaceuticals	105,975	31.2	105.4	103,424	30.5	97.6	
Dispensing	50,228	14.8	109.3	48,994	14.4	97.5	
Beauty Products	99,286	29.2	108.5	100,363	29.6	101.1	
Health Foods	11,431	3.4	111.4	10,479	3.1	91.7	
Sanitary Goods	42,329	12.5	106.0	40,996	12.1	96.9	
Convenience Goods	46,329	13.6	103.4	47,068	13.9	101.6	
Foods	34,294	10.1	110.9	36,772	10.8	107.2	
Stores Total	339,646	100.0	106.8	339,105	100.0	99.8	
Wholesale	31,388	-	108.3	35,689	-	113.7	
Subtotal	371,034	-	106.9	374,795	-	101.0	
Long-term Care	2,243	-	101.9	2,410	-	107.5	
Inter-segment Eliminations	-2	-	-	-1	-	-	
Total	373,275	-	106.9	377,203	-	101.1	


Most Affected by Lower Reseller Purchases : Pharmaceuticals Beauty Products Health Foods Sanitary Goods

- Dispensing : A reduction in government-mandated drug prices and medical care fees
- Beauty Products : Robust sales of high value-added and new products
- Foods : Functional improvements made through store renovations and layout changes
- Wholesale : Increase in number of clients
- Long-term Care : Conversion of Yamamoto Service into subsidiary in April 2016 contributed to earnings

Gross Profit Margin Improvement

こ ココカラファイン

Drugstore product sales: Trend in comparable store gross profit (Cocokarafine Healthcare)



of high value-added products, store standardization and increased sales promotion efficiency

SG&A Expenses Improvement


こ ココカラファイン




<u>From Q3</u>: Cost controls \rightarrow Absorbed upfront spending, keeping expense ratio on par with year-earlier level

(Figures in parentheses are the number of applicable stores)

こうコカラファイン






Effect 4 Drug price revisions

Decline in drug price margins

こ ココカラファイン

Dispensing business: Trend in all-store gross profit



Measures to address medical care fee revisions drove growth in full-year gross profit (YoY+JPY92mn)

Consolidated Balance Sheet

こ ココカラファイン

End Mar. 2016

End Mar. 2017



Comparison with end March 2016

(Million yen)

Current assets	+3,987	Non-current assets	+571	Liabilities	-723	Net assets	+5,282
Cash and Equivalents	+541	Property, plant and equipment	-268	Current liabilities Non-current	-1,061	Retained earnings	+5,197
Accounts receivabletrade	+1,209	Intangible fixed assets	+828	liabilities	+337		
Inventories	+328	Investments and	+11				
Accounts receivable-other	+1,971	other assets	711				


Consolidated Cash Flow Statement

こ ココカラファイン

(Unit: JPYmn)

FY03/16

FY03/17



Situation in FY03/17

Cash flows from op activities	erating	Cash flows from inves activities	ting	Cash flows from financial activities		
Income before income taxes and minority	11,339	Purchase of property, plant and equipment	-3,404	Increase (decrease) in short-term borrowings	-600	
interests Depreciation and	3,698	Purchase of intangible fixed assets	-761	Cash dividends paid	-1,842	
amortization Increase (decrease) in	3,030	Payments for transfer of business	-407			
accounts receivable - other	-1,265	Purchase of shares of subsidiaries resulting in change	-837	Net increase (decreation cash and cash equivation	alents 539	
Income taxes paid	-7,154	in scope of consolidation		C		



FY03/17 Key Measures

- Revitalization of existing stores through renovations
- Optimization by store formats
- Trend in renovated store numbers
- Customer strategy that leverages Cocokara Club Card
- Promotion of customer loyalty based on adoption and usage of prepaid payment functionality
- Establishing one-to-one (personalized) marketing using diverse sales promotion media
- · Expanding interaction with customers and providing highly convenient services
- Further store productivity improvements
- · ICT deployment to improve in-store work efficiency and added value


Revitalization of Existing Stores through Renovations

こ コンカラファイン

From FY03/15, promoted store optimization based on store formats through renovations Expanded the number of stores under the Cocokara Fine brand in conjunction with new store openings and store renovations


	FY03/17 result	FY03/18 plan		
 Imber of renovated stores cluding sign changes and small renovations)	103stores	174 _{stores}		
(Of which, over JPY5mn)	67stores	89stores		





Customer Strategy that Leverages Cocokara Club Card


Promotion of customer loyalty based on adoption and usage of prepaid payment functionality



こう コンカラファイン


【 こっカラファイン

Expanding interaction with customers and providing highly convenient services



こ コンカラファイン

ICT deployment to improve in-store work efficiency and added value





FY03/18 Forecasts

Store Openings and Closings (Actual and Planned)

こ ココカラファイン

		FY03/16	Results	FY03/17	'Results	FY03/1	8 Plan
			Prescriptions		Prescriptions		Prescriptions
Open	Drugstore	16	1	17	2	23	6
*	Standalone dispensaries	3	3	18	18	10	10
	· · ·	19	4	35	20	33	16
Close	Drugstore	-51	-4	-37	-2	-17	-2
*	Standalone dispensaries	-2	-2	-1	-1	-1	-1
	· ·	-53	-6	-38	-3	-18	-3
Store	Drugstore	-6	-6	-1	-1	-1	-1
format change	Standalone dispensaries	6	6	1	1	1	1
	· · ·	0	0	0	0	0	0
End of	Drugstore	1,178	103	1,157	102	1,162	105
period	Standalone dispensaries	129	129	147	147	157	157
		1,307	232	1,304	249	1,319	262

* Store openings and closures include changes in dispensing bases

(Million yen)


	FY03/17 Results	FY03/18 Plan
Capital investment	6,419	5,700
Total cash flow	11,059	11,857
Net income	7,037	7,900
Depreciation	3,698	3,667
Amortization of goodwill	324	290

こ ココカラファイン

		1H (AprSep.)					Full-Year					
		FY03/17 Results		FY03/18 Forecast		FY03/17 Results		FY03/18 Forecast				
		Million yen	% of net sales	Million yen	% of net sales	YoY (%)	Million yen	% of net sales	Million yen	% of net sales	YoY (%)	
	Net sales	188,485	100.0	195,000	100.0	103.5	377,203	100.0	390,000	100.0	103.4	
	Drugstore & Dispensing	169,924	90.2	175,507	90.0	103.3	339,105	89.9	350,770	89.9	103.4	
	Wholesale & other	18,561	9.8	19,492	10.0	105.0	38,098	10.1	39,229	10.1	103.0	
	Gross profit	47,680	25.3	50,273	25.8	105.4	97,053	25.7	101,873	26.1	105.0	
	SG&A	43,784	23.2	45,173	23.2	103.2	86,894	23.0	90,473	23.2	104.1	
Op	perating income	3,896	2.1	5,100	2.6	130.9	10,159	2.7	11,400	2.9	112.2	
0	rdinary income	5,158	2.7	6,300	3.2	122.1	12,507	3.3	13,800	3.5	110.3	
	Net income	2,915	1.5	3,700	1.9	126.9	7,037	1.9	7,900	2.0	112.3	


Consolidated Sales & Ordinary Income (Trends and Plan)

こ ココカラファイン



こ ココカラファイン

Medium-term plan through FY03/20.



Cocokara Fine Inc.

http://corp.cocokarafine.co.jp/english/

The information published on this book is intended to provide financial data and management indicators on Cocokara Fine Inc. and its affiliates (hereinafter, "the Company"). Nevertheless, the Company does not make any warranties or statements regarding the content of this information.

Some of the information appearing on this book contains mention of the future performance of the Company. These forward-looking statements do not guarantee future performance and include risk and uncertainties. The actual performance of the Company may differ from such statements due to changes in the business environment or other factors.